One of the representatives is emicizumab, which can bind to FIXa and FX/FXa at the mmol level and remarkably reduce the risk of bleeding in hemophilia A patients (Shima et al., 2016; Kitazawa et al., 2017; Mahlangu et al., 2018). The gene discussed is F10; the disease is hemophilia A.